Leadership Overview
Avara Pharmaceutical Services has 5 executives leading key functions including strategy, operations, finance, human resources, and market leadership.
Driven by a commitment to manufacturing excellence, Avara Pharmaceutical Services provides comprehensive pharmaceutical solutions, focusing on sterile injectables and oral solid dose manufacturing to meet critical healthcare needs.
Driven by a commitment to manufacturing excellence, Avara Pharmaceutical Services provides comprehensive pharmaceutical solutions, focusing on sterile injectables and oral solid dose manufacturing to meet critical healthcare needs.
Leadership Roles at Avara Pharmaceutical Services
Amit Arora - Chief Executive Officer
Amit Arora, the Chief Executive Officer at Avara Pharmaceutical Services, directs the overarching corporate strategy and operational vision. Arora guides the organization's expansion in aseptic liquid filling and sterile pharmaceutical manufacturing, aligning all functions with market demands for oral solid dose and sterile injectables. This leadership role involves fostering innovation in packaging solutions and ensuring compliance with stringent industry regulations. Arora's strategic direction drives Avara Pharmaceutical Services' position as a key manufacturing partner. The Chief Executive Officer's focus remains on sustainable growth and enhancing the company's service offerings. By cultivating strong relationships with stakeholders, Arora ensures the company's long-term success and market impact. This executive's mandate includes optimizing resource allocation across all departments to support the company's mission.
Kunal Bahl - Group Chief Financial Officer, Finance Lead For Automotive & Pharma
Kunal Bahl, the Group Chief Financial Officer, Finance Lead For Automotive & Pharma at Avara Pharmaceutical Services, manages all financial operations and strategic fiscal planning. Bahl oversees the financial health of the pharmaceutical manufacturing division, ensuring robust capital management for aseptic liquid filling and sterile pharmaceutical production. The Group Chief Financial Officer's expertise guides investment decisions in oral solid dose manufacturing and packaging solutions. Kunal Bahl's financial leadership supports the company's growth initiatives and its ability to provide sterile injectables. This executive ensures fiscal discipline and optimizes financial performance across all operational segments. Bahl's responsibilities include managing budgets, forecasting revenue, and securing funding for capital expenditures. The Group Chief Financial Officer's strategic financial insights are vital for Avara Pharmaceutical Services' sustained market presence and expansion.
Larry Lee - Chief Operating Officer
Larry Lee, the Chief Operating Officer at Avara Pharmaceutical Services, executes the day-to-day operational strategies for manufacturing and packaging. Lee oversees the aseptic liquid filling processes and sterile pharmaceutical production, ensuring efficiency and quality control. The Chief Operating Officer's responsibilities extend to managing the oral solid dose manufacturing lines and packaging solutions, directly impacting product delivery timelines. Larry Lee's operational oversight is critical for maintaining the high standards required for sterile injectables. This executive drives process improvements across all production facilities located in Norman, Oklahoma. By optimizing workflows, Lee enhances the company's capacity to meet client demands for complex pharmaceutical products. The Chief Operating Officer's role involves close collaboration with supply chain management and quality assurance teams to guarantee seamless operations and regulatory adherence.

Robert Rothmann - President
Robert Rothmann, the President at Avara Pharmaceutical Services, drives market strategy and business development initiatives. Rothmann focuses on expanding the company's reach in aseptic liquid filling and sterile pharmaceutical services, identifying new opportunities for oral solid dose manufacturing and packaging solutions. The President's leadership is key to forging strategic partnerships and enhancing Avara Pharmaceutical Services' market position. Robert Rothmann's vision guides the company's efforts in delivering high-quality sterile injectables. This executive oversees client relations and ensures that the company's offerings meet evolving industry needs. Rothmann's strategic acumen is instrumental in navigating the competitive landscape and achieving sustained business growth. The President's role involves championing the company's commitment to manufacturing excellence and client satisfaction.
Richard Mark - Chief Human Resources Officer
Richard Mark, the Chief Human Resources Officer at Avara Pharmaceutical Services, leads all human capital strategies and organizational development initiatives. Mark oversees talent acquisition, employee relations, and performance management, ensuring a skilled workforce for aseptic liquid filling and sterile pharmaceutical manufacturing. The Chief Human Resources Officer's role is crucial in fostering a culture of compliance and safety within the oral solid dose and sterile injectables production environments. Richard Mark's strategic HR leadership supports Avara Pharmaceutical Services' operational objectives by attracting and retaining top talent. This executive develops programs that enhance employee engagement and professional growth. The Chief Human Resources Officer ensures that HR policies align with the company's mission and regulatory requirements, contributing to overall organizational effectiveness and stability.
Explore Leadership Teams in Manufacturing
Revolution Medicines Inc is a pioneering biotechnology company committed to revolutionizing treatment for patients battling cancer. They are driven by a singular mission: the discovery, development, and delivery of innovative, targeted medicines, particularly focusing on what are known as RAS-addicted cancers, which represent a significant proportion of new human cancer diagnoses. The company has developed a groundbreaking tri-complex inhibitor platform to create a portfolio of RAS(ON) inhibitors, enabling a differentiated approach to target what was previously considered an undruggable molecular target in oncology. Through their tireless efforts and commitment to transformative science, they are building a deep pipeline of therapeutic candidates intended to change the standard of care for patients with these challenging diseases.
Company Leadership AS

SK
Purdue Pharma is a developer and provider of prescription medicine. They were founded in 1892 and are currently headquartered in Stamford, Connecticut.
Company Leadership MK
MZ
KD
HG
Founded in 1997 and headquartered in West Columbia, South Carolina, Nephron Pharmaceuticals manufactures generic respiratory medications.
Company Leadership AG
JM
PK
Shionogi & Co., Ltd. is a Japanese pharmaceutical company dedicated to developing innovative treatments that improve patient lives worldwide. With a longstanding focus on addressing pressing global health challenges, the company has been a pioneer in discovering and delivering novel therapies for infectious diseases, including antibiotics, HIV, influenza, and emerging viral threats such as COVID-19. Shionogi combines in-house research and development with strategic collaborations across industry, government agencies, biotech companies, and academic institutions to accelerate the advancement of its scientific programs and bring meaningful therapies to patients with urgency and precision.
Company Leadership
TK
TN
